Journal of Medicinal Chemistry p. 3321 - 3332 (1993)
Update date:2022-09-26
Topics:
Daines, Robert A.
Chambers, Pamela A.
Pendrak, Israil
Jakas, Dalia R.
Sarau, Henry M.
et al.
A series of trisubstituted pyridines have been prepared that exhibit in vitro leukotriene B4 (LTB4, 1) receptor antagonist activity.Previous disubstituted pyridines from these labs showed high affinity for the LTB4 receptor but demonstrated agonist activity in functional assays (e.g., 2, Ki = 1 nM).Compound 4, the initial lead compound of this new series, showed only modest affinity by comparison (Ki = 282 nM); however, 4 was a receptor antagonist with no demonstrable agonist activity up to 10 μM.Subsequent modifications of the lipid tail and aryl head group region led to the discovery of aniline 50 (SB 201146).This compound, also free of agonist activity, possesses high affinity for the LTB4 receptor (Ki = 4.7 nM).
View MoreZhuhai Rundu Pharmaceutical co.,Ltd
Contact:+86-756-7630755
Address:No.6,North Airport Road,Sanzao Town,Jinwan District
Contact:0086-29-88315623
Address:S711, Innovation Bldg No.25 Gaoxin 1st Rd, Xian P.R of China 710075
SuZhou Ascepion Pharmaceuticals, Inc.(expird)
Contact:0512-86881668
Address:Building C,68Xingqing Road,Suzhou,China.
Chengdu Baishixing Science and Technology Industry Co., Ltd.
website:http://www.cd-bsx.com
Contact:+86-28-88531548
Address:#217,North of Industry Road,Heshan Town,Pujiang County,Chengdu,Sichuan,China.
Shanghai Maxchemco Chemical Industry Co., Ltd.
Contact:(86)21-51079223
Address:No.1305-8, B241, the Ecust Park, Huajing Road, Xuhui District, Shanghai
Doi:10.1021/jo00040a064
(1992)Doi:10.1021/ja3113752
(2013)Doi:10.1002/aoc.2952
(2013)Doi:10.1021/jo302549v
(2013)Doi:10.1246/cl.1992.807
(1992)Doi:10.1021/ja00975a029
(1966)